Medtronic Beats Q2 Estimates, Raises Full-Year Guidance on Broad Growth
- Medtronic beat Q2 earnings and revenue estimates, with revenue up 5% and adjusted EPS of $1.25
- Strength was broad-based across businesses and geographies
- Diabetes products grew nearly 10%
- Medtronic raised full-year fiscal 2024 guidance, now expecting 4.75% revenue growth (up from 4.5%)
- New adjusted EPS guidance is $5.13-$5.19, increased from $5.08-$5.16